- Rich nations stockpiling a billion more COVID-19 shots than needed: report (reuters.com)Short of vaccine, states find hidden stashes in their own backyards (pharmacist.com)
Rich countries are on course to have over a billion more doses of COVID-19 vaccines than they need, leaving poorer nations scrambling for leftover supplies as the world seeks to curb the coronavirus pandemic...In an analysis of current supply deals for COVID-19 vaccines, the ONE Campaign said wealthy countries, such as the United States and Britain, should share the excess doses to “supercharge” a fully global response to the pandemic...the United States, the European Union, Britain, Australia, Canada and Japan have already secured more than 3 billion doses - over a billion more than the 2.06 billion needed to give their entire populations two doses...READ MORE
- With vaccines in more stores, pharmacies go on hiring spree (pharmacist.com)
Dozens of pharmacy chains and grocery stores with pharmacy counters are slated to start offering COVID-19 vaccinations this week, creating a wealth of employment opportunities. The companies are vying with one another—offering lucrative signing bonuses, in some cases—to hire established pharmacists, pharmacy technicians, student pharmacists, nurses, and other help. CVS Health is working toward 15,000 new vaccine-related hires, Walgreens has targeted 9,000, Kroger plans to recruit nearly 1,000 health care workers, and Rite Aid is looking to fill more than 2,000 pharmacy jobs...READ MORE
- The first coronavirus vaccines have arrived. Here’s where the rest stand. (biopharmadive.com)
Study results showed vaccines from J&J; and Novavax to be effective against COVID-19. But seemingly weaker protection versus new virus variants have raised concerns...Scientists, drugmakers and governments have moved with unprecedented haste to develop a vaccine against the new coronavirus...The fastest of them have completed studies proving their vaccines can protect against COVID-19. A half dozen shots from developers in the U.S., U.K., Germany, China and Russia have now been cleared by regulators for emergency use...READ MORE
- Pfizer, Johnson & Johnson balk at shareholders’ push for COVID-19 vaccine pricing info (fiercepharma.com)
What's the rationale behind COVID-19 vaccine and drug prices? You don’t have a need to know—or so say a couple of the leading contenders...Two major players in the pandemic fight, Pfizer and Johnson & Johnson, are urging the Securities and Exchange Commission to forestall shareholder resolutions that would require them to disclose how they set prices on their COVID-19 vaccines...Several not-for-profit groups are pushing the two companies—along with fellow pharmas Eli Lilly, Gilead, Merck & Co. and Regeneron—for information on their drug and vaccine pricing decisions, citing the federal money all have received, either for supplies, R&D or manufacturing scale-up. Or all three...READ MORE
- Pfizer seeks to store vaccine at higher temperatures, easing logistics (reuters.com)
Pfizer Inc and BioNTech SE have asked the U.S. health regulator to relax requirements for their COVID-19 vaccine to be stored at ultra-low temperatures, potentially allowing it to be kept in pharmacy freezers...Approval by the Food and Drug Administration could send a strong signal to other regulators around the world that may ease distribution of the shot in lower-income countries...The companies have submitted new temperature data to the FDA to support an update to the current label that would allow vials to be stored at -25 to -15 degrees Celsius (-13°F to 5°F) for a total of two weeks...READ MORE
- Pfizer to nearly halve COVID-19 vaccine production timeline, sterile injectables VP says (fiercepharma.com)
DNA production—the first step in Pfizer's vaccine manufacturing process—could soon take just nine to 10 days, rather than 16...With an upsized production goal of 2 billion COVID-19 vaccine doses this year, Pfizer and its German partner BioNTech aren’t resting on their laurels now that their shot, Comirnaty, has emergency nods in the U.S., Europe and beyond. As the companies continue to build out capacity, manufacturing efficiency is getting its own boost...The time it takes the company to produce a COVID-19 vaccine batch could soon be cut from 110 days to an average of just 60...READ MORE
- FDA clears Lilly’s COVID-19 antibody cocktail for emergency use (biopharmadive.com)
The Food and Drug Administration...cleared an antibody drug cocktail from Eli Lilly for emergency use for treating people recently diagnosed with COVID-19...The cocktail, a combination of two coronavirus-targeting antibodies, is authorized only for people with mild or moderate symptoms of COVID-19, but who are at high risk of the disease's worst effects due to age, underlying medical conditions or other preexisting conditions...The combination pairs Lilly's bamlanivimab...with another antibody called etesevimab that the drugmaker developed in partnership with China's Junshi Biosciences. Each antibody targets a separate section of the "spike" protein used by the SARS-CoV-2 virus to breach the body's cells — a feature designed to preserve the drug's effectiveness even as the virus mutates...READ MORE
- WHO authorizes AstraZeneca’s COVID vaccine for emergency use (kold.com)
The World Health Organization has granted an emergency authorization to AstraZeneca’s coronavirus vaccine, a move that should allow the U.N. agency’s partners to ship millions of doses to countries worldwide as part of a U.N.-backed program to tame the pandemic...the WHO said it was clearing the AstraZeneca vaccines made by the Serum Institute of India and South Korea’s AstraZeneca-SKBio...“Countries with no access to vaccines to date will finally be able to start vaccinating their health workers and populations at risk,” said Dr Mariângela Simão, the WHO’s Assistant-Director General for Access to Medicines and Health Products....READ MORE
- Nevada climbs out of bottom in administering vaccine, CDC says (reviewjournal.com)
Nevada no longer has one of the worst COVID-19 vaccination rates per capita in the U.S., according to federal data...The Silver State had consistently ranked among the bottom five states at administering vaccine for weeks. It now ranks 12th worst, the Centers for Disease Control and Prevention reported...READ MORE
- AstraZeneca, Oxford race to update COVID-19 vaccine as study flags weak action against variant (fiercepharma.com)
It didn’t take long before a morale boost for AstraZeneca’s COVID-19 vaccine was overshadowed by disappointment over its waned protection against a newly emerged coronavirus variant...A new study has found AZ’s COVID-19 shot offered “minimal protection” against mild to moderate disease caused by the B.1.351 variant, which was first identified in South Africa, the University of Oxford, the original developer of the vaccine, said...READ MORE